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Abstract. – OBJECTIVE: The aim of this re-
view is to describe the most common recurring 
and chronic upper respiratory tract infections 
(URTI) in children and discuss the role of bac-
terial interference and bacteriotherapy in their 
prevention and treatment.
MATERIALS AND METHODS: A literature 
review has been performed on the following 
topics: acute otitis media, adenoiditis, tonsilli-
tis, rhinosinusitis, microbiotics and the role of 
bacterial interference, and bacteriotherapy in 
the prevention and treatment of URTI.
RESULTS: Research studies into the charac-
teristics of the microbiological flora and its role 
in the pathogenesis of URTI have focused on a 
single pathogen, on resistance to and ineffective-
ness of antibiotic therapies, or on the persistence 
of bacterial biofilm. Recent evidence supports a 
central role of the existing microbial ecosystem 
in the pathogenesis of respiratory disease. In the 
light of this, new therapeutic approaches include 
the implantation and persistence within the nor-
mal microflora of relatively innocuous “effector” 
bacteria that can competitively exclude or prevent 
the outgrowth of potentially disease-causing bac-
teria. Recently, a retrospective and observational 
study demonstrated that S. salivarius 24SMB and 
S. oralis 89a nasal spray could be effective in the 
prevention of recurrent otitis media in a real-life 
setting. Other studies have focused on the role of 
bacteriotherapy in children with beneficial effects 
in the prevention of URTI. 
CONCLUSIONS: The results of previous stud-
ies on the role of bacteriotherapy in paediat-
ric URTI suggest that the use of bacterial inter-
ference phenomena through bacteriotherapy is 
a feasible, safe approach and deserves proper 
consideration as a promising therapeutic strat-
egy against URTI.
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Introduction
Recurring and/or chronic inflammations/
infections of the upper respiratory tract are ex-
tremely frequent in the early years of life while 
children are still developing immune properties.
Immediately after birth, the upper airway rap-
idly becomes colonized by commensal and poten-
tially pathogenic bacteria: within the first year, 
50 to 100% of infants are colonized by Strepto-
coccus pneumoniae, Haemophilus influenzae and 
Moraxella catarrhalis1. In general, colonization 
rises gradually and peaks at 2-3 years of life, then 
decreases until 15-16 years, eventually increas-
ing again in adults older than 65 years2. Although 
variable, the colonization rates in healthy adults 
are lower than those in children. Colonization is a 
dynamic phenomenon varying not only from de-
livery, through childhood, adolescence, adult and 
advanced age, but also according to genetic back-
ground variables, socioeconomic conditions and 
geographic areas3-5. The upper airway is a major 
ecological reservoir of bacterial species: as in the 
gut, the early pharyngeal microbiome influences 
colonization and respiratory tract health6. Protec-
tive and potentially pathogenic bacteria have been 
isolated in populations of healthy children, such as 
persistent or transient pathogens of the naso- and 
oropharynx. These are: Neisseria, Streptococcus 
pyogenes, Haemophilus influenzae, Staphylococ-
cus aureus, Actinomyces, Bacteroides, Prevotel-
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la, Porphyromonas, Peptostreptococci, and Fu-
sobacterium spp7,8. Pathogens enter the host by 
colonizing the nasopharyngeal mucosal epitheli-
um, but identifiable disease occurs in only a small 
percentage of persons who are colonized. 
To date, research into the characteristics of the 
microbiological flora and their role in the patho-
genesis of recurring and chronic upper respirato-
ry tract infections (URTI) has focused on a single 
pathogen, on resistance to and ineffectiveness 
of antibiotic therapies, or, more recently, on the 
presence/persistence of bacterial biofilm9. The 
worldwide emergency of bacterial resistance to 
antibiotics has led to the need for new methods of 
combating bacterial infections10. This emergency 
is aggravated by the long delay in the develop-
ment of new antibacterial agents. If the design 
of new agents proves to be in the right direction, 
such progress would not resolve all current resis-
tance problems; in addition, it should be remem-
bered that the use of antibacterial agents selects 
not only resistant bacteria but may also negatively 
affect normal bacterial flora even if with differ-
ent degree of interference11. The administration 
of antimicrobial agents disrupts normal human 
flora, further reducing our defense against in-
fections12. Modern molecular culture-indepen-
dent approaches to chronic respiratory diseases 
have opened a promising scenario on microbial 
communities associated with the human body 
and their role in health and diseases, but consen-
sus does not yet exist on the microbial ecology 
associated with chronic diseases. Last-century 
theories about the mechanisms involved in infec-
tious episodes viewed the lymphatic vessels and 
the immune cells of the mucosa grouped in the 
specific area named Waldeyer’s ring as the most 
important line of defense of our body from ex-
ternal attacks. Lymphoid tissue in Waldeyer’s 
ring structures (namely adenoids, palatine tonsils, 
tubal tonsils and lingual tonsils) is predominantly 
characterized by crypts and mucosal irregulari-
ties, rendering them more susceptible to antigenic 
responses through the acquired immunity mecha-
nisms. Nowadays, the upper airway microbiome, 
including saprophytic, commensal, pathogenic 
bacteria, fungi, and viruses, is considered the first 
line of defense of our body; when the inflamma-
tory response to pathogenic stimuli starts, a sit-
uation of disequilibrium or dysbiosis opens the 
door to clinically evident infection and recurring/
chronic disease 13. The aim of this review is to 
describe the most common recurring and chron-
ic inflammations of the upper respiratory tract in 
children, such as acute otitis media, adenoiditis 
and tonsillitis, and rhinosinusitis, and discuss the 
role of bacterial interference and bacteriotherapy 
in their prevention and treatment.
Materials and methods
A literature review has been performed on ar-
ticles retrieved from PubMed and Scopus on the 
following topics: acute otitis media, adenoiditis, 
tonsillitis, rhinosinusitis, microbiotics and the 
role of bacterial interference, and bacteriotherapy 
in the prevention and treatment of URTI.
Results
Acute Otitis Media
Acute otitis media (AOM) is the most common 
bacterial infection in young children, with con-
sequences on hearing and associated symptoms 
that in some cases may also affect behavior and 
language development14,15. Large amounts of an-
tibiotics are prescribed for this pathology, espe-
cially for those children with recurring episodes. 
The peak incidence of AOM is at 1 2 years of age15. 
The majority of AOM episodes occur concurrent-
ly with, or soon after, viral URTI. Chonmaitree et 
al16 found a high prevalence of symptomatic viral 
URTI among young children; >60% of cases were 
complicated by AOM and/or otitis media with ef-
fusion (OME). In addition to young age and im-
mature Eustachian tube function, specific viral 
infection, such as adenovirus, respiratory syncy-
tial virus (RSV), coronavirus and viral load, are 
predictors of URTI complicated by AOM. 
The risk of developing another episode within 
one month after the onset of the primary infection 
is estimated at 35%; in the majority of cases (75%) 
the new episodes are infections by new bacterial 
strains, suggesting an underlying susceptibility to 
recurrent AOM. The remaining 25% are from ei-
ther re-infection with the same bacterial strain or 
treatment failure17. 
About 5% of children are “prone” to otitis me-
dia, defined as three episodes within a 6-month 
time span or 4 events within 12 months18. More re-
cently, the definition of “stringent otitis prone” was 
proposed when the clinical diagnosis is confirmed 
by bacterial culture of the middle ear fluid19.
Bacterial culture confirmation is of the utmost 
importance: signs and symptoms are often aspe-
cific and empiric clinical diagnosis doesn’t allow 
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differentiation of OME (i.e. the presence of fluid 
in the middle ear without signs or symptoms of 
acute infection) from AOM, which could limit 
unnecessary antibiotic use and microbial flora al-
terations. OME often resolves spontaneously, and 
only rarely may insertion of a tympanostomy tube 
be required for fluid drainage20.
Disease etiology and pathogenesis are 
multi-factorial and begin with colonization of 
mucosal surfaces in the upper respiratory tract by 
AOM pathogens21.
The most common bacteria associated with 
AOM are Streptococcus pneumoniae, Haemophi-
lus influenzae and, less often, Moraxella catarrh-
alis and group A β-streptococci15. These bacteria 
originate and diffuse from the nasopharynx to the 
middle ear cavity by way of the Eustachian tube. 
Secretory otitis media (SOM) is the most com-
mon sequela of AOM; it is characterized by per-
sistence of effusion in the middle ear cavity20. One 
or more of S. pneumoniae, H. influenzae, or M. 
catarrhalis are found in approximately 30% of pa-
tients with suppurative otitis media (SOM)15,22. A 
strong correlation between the nasopharyngeal flo-
ra and middle ear infections has been found. Naso-
pharyngeal colonization by H. influenzae, S. pneu-
moniae and/or M. catarrhalis in the first year of 
life is associated with an increased risk of recurrent 
AOM or SOM compared with children who remain 
free of colonization. The factors that influence col-
onization are multiple and not entirely clear. There 
is no doubt that the local host immune response 
plays an important regulatory role in the traffick-
ing of pathogens in the upper airway. Other factors 
influencing nasopharyngeal carriage rates are: age, 
season, type of child day care, number of siblings, 
acute respiratory illness, diet (breast-feeding vs. 
bottle-feeding), and sleeping position. In adults, 
other factors are implicated: presence of children 
at home or at the workplace, chronic obstructive 
pulmonary disease, obesity, immunosuppression, 
allergic conditions, and acute sinusitis2.
In children with recurrent AOM potential 
pathogens may constitute > 90% of the total bacte-
rial count15,22. In contrast, among healthy children 
viridans streptococci are predominant23. Data from 
Syrjanen et al24 show that S. pneumoniae carriage 
is lower during health (13-43%) than during AOM 
episodes, reaching 97-100% carriage in pneu-
mococcal AOM. Otitis-prone children tend to be 
colonized more often than non-otitis-prone chil-
dren25. In addition, nasopharyngeal colonization 
with antibiotic-resistant bacteria is associated with 
an increased incidence of unresolved otitis media 
2. Epidemiologic studies have shown that the risk 
of S. pneumoniae colonization differs according to 
whether H. influenzae, M. catarrhalis, and Staph-
ylococcus aureus are also present26-28. Bacteri-
um-bacterium interaction may also impact AOM 
incidence. Simultaneous colonization by multiple 
AOM pathogens is associated with a greater risk 
of AOM than the risk associated with colonization 
by a single AOM pathogen 29,30. Members of the 
normal flora, such as alpha-hemolytic streptococ-
ci, inhibit the growth of AOM pathogens in vitro31. 
Healthy children are more likely than children with 
AOM to be colonized by alpha-hemolytic strep-
tococci32-34. Lower numbers of alpha-hemolytic 
streptococci have been found in the nasopharynx 
of children who are prone to otitis media compared 
with those who are not prone and in those with 
SOM compared with healthy children15. Collec-
tively, these data indicate that certain commensals 
influence the risk of AOM pathogen colonization 
and the subsequent risk of disease 21.
Adenoiditis/Tonsillitis
The adenoids are believed to play a role in 
several infectious and non-infectious pathologies 
of upper airways35. Since the 1980s, it has been 
clear that they are implicated in the etiology of 
OMA36-41, rhinosinusitis36,39,42, adenotonsillitis43 
and chronic nasal obstruction44,45. The adenoids 
in healthy children contain potential respiratory 
pathogens43,46. The nasopharynx and adenoids of 
healthy individuals, unlike subjects with recur-
rent URTI, are generally colonized by aerobic 
and anaerobic microorganisms that are able to in-
terfere with the growth of potential pathogens47,48.
Exposure to antimicrobial therapy can alter 
the colonization patterns and select for resistant 
organisms. Production of β-lactamase is one of 
the major mechanisms of resistance of these or-
ganisms. Maintaining the beneficial effects of 
normal flora by avoiding unnecessary exposure 
to antimicrobial therapy may be a useful tool in 
preventing colonization of the adenoids and/or 
tonsils by potential pathogens35.
Adenoids are liable to inflammatory changes 
(viral, allergic) and frequently are infected con-
comitantly with the tonsils. Acute adenoiditis 
may occur alone or in association with rhinitis or 
tonsillitis. Chronic adenoiditis may result from 
repeated acute attacks or from persistent infec-
tion. Adenoid hypertrophy is defined as an en-
largement of the adenoids, which may be simple 
or inflammatory, and may be linked to infection. 
Recurring adenotonsillitis is often a bacterial-vi-
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ral illness35. Along with recurring tonsillitis, ad-
enoid hypertrophy and recurring adenotonsillitis 
constitute adenotonsillary disease characterized 
by persistent bacterial infection35.
Periodic episodes of fever and upper airway 
obstruction are the major symptoms of adenoid-
itis and recurring tonsillitis.
Recurring or chronic inflammation of the ad-
enoids and faucial tonsils leads to chronic activa-
tion of the cell-mediated and humoral immune re-
sponses, resulting in hypertrophy of the lymphoid 
tissue. This hypertrophic tissue is the cause for 
the prominent clinical symptoms: obstruction of 
the upper airways, snoring, and sleep apnea for 
adenoiditis or sore throat, dysphagia and halitosis 
for recurring tonsillitis49.
In adenoids and tonsils, bacteria, mostly Staph-
ylococcus aureus, Haemophilus sp., and Strepto-
coccus sp., persist predominantly intracellularly 
and within mucosal biofilms50. As with recurring 
tonsillitis and adenoiditis, the most likely mecha-
nism for pathogenesis is the endogenous reactiva-
tion of these persistent pathogenic bacteria51,52. In 
recent research, biofilm formation was identified 
as playing a pivotal role in the etiology of numer-
ous chronic otorhinolaryngologic infections, such 
as chronic rhinosinusitis, chronic otitis media, 
and adenotonsillar disease, which do not respond 
to conservative antimicrobial treatment49,53,54.
Bacteria in biofilms are surrounded by a car-
bohydrate-containing matrix on or within the ad-
enotonsillar epithelium, and communicate with 
each other by a process called quorum sensing 
(QS), which responds to the density of cell pop-
ulations55,56. Biofilms in the adenoids may act as 
reservoir for chronic otitis media and chronic rhi-
nosinusitis57. 
Thus, adenoidectomy is shown to be a plausi-
ble therapy for two diseases: as surgical removal 
of an infectious source in the nasopharynx and as 
first-line therapy for medically refractory, uncom-
plicated paediatric rhinosinusitis58,59.
Conservative treatment of moderate grades of 
hypertrophy with bacterial compounds must con-
sider these bacterial persistence strategies.
Rhinosinusitis
The upper respiratory tract, including the na-
sopharynx, serves as a reservoir for pathogens ca-
pable of causing URTI, including rhinosinusitis60. 
Potential pathogens can relocate during a viral re-
spiratory infection, from the nasopharynx into the 
sinus cavity, causing a sinusitis61. The nasopharyn-
geal carriage of upper respiratory tract pathogens, 
such as S. pneumoniae, H. influenzae and M. ca-
tarrhalis, can, however, occur in healthy subjects; 
it increases significantly in children during respi-
ratory diseases and in sinusitis8,34. The nasophar-
ynx of healthy individuals is generally colonized 
by relatively non-pathogenic aerobic and anaer-
obic organisms48,62, some of which are able to in-
terfere with the growth of potential pathogens63. 
This phenomenon is called bacterial interference8. 
These organisms include, amongst others, aerobic 
microorganisms such as alpha-hemolytic strepto-
cocci (mostly Streptococcus mitis and Streptococ-
cus sanguinis)64 and anaerobic bacteria (Prevotella 
melaninogenica and Peptostreptococcus anaer-
obius)65. The absence of interference between 
organisms may explain the greater possibility of 
recruiting pathogens in these children. The colo-
nization of interfering organisms can play a role in 
preventing colonization by pathogens and the de-
velopment of URTI, including sinusitis. Exposure 
to direct and indirect smoking can increase oral 
colonization with pathogenic bacteria and decrease 
the number of organisms that interfere with their 
growth. The flora of smokers contains fewer aer-
obic and anaerobic organisms with interfering ca-
pability and more potential pathogens as compared 
with nonsmokers66. The high number of pathogens 
and the low number of interfering organisms found 
in the nasopharynx of smokers reverts to normal 
levels after complete cessation of smoking67. 
The pattern of many URTI, including sinus-
itis, evolves in different phases. The initial phase 
is often a viral infection that usually lasts up to 10 
days, after which it manifests a complete recovery 
in most subjects68. However, a small number of 
patients with viral sinusitis may develop second-
ary acute bacterial infection8. This is generally 
caused by optional aerobic bacteria (i.e., S. pneu-
moniae, H. influenzae, and M. catarrhalis)8, also 
called “the infernal trio”69. The maxillary sinus 
has 26% of S. pneumoniae, 28% of H. influenzae 
and 6% M. catarrhalis, plus 8% of S. aureus70. 
If the episode does not resolve, anaerobic bacte-
rial flora becomes predominant over time8. The 
dynamics of these changes in bacterial flora have 
been demonstrated by performing serial cultures 
in patients with maxillary sinusitis71. It could be 
assumed that chronic sinusitis is an extension of 
an acute non-resolved infection8. The acute exac-
erbation of chronic sinusitis is a sudden worsen-
ing of chronic sinusitis (worsening of symptoms 
in progress or the appearance of new symptoms). 
Epithelial cells constitute the first barrier to 
pathogenic agents such as viruses or bacteria. 
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Goblet cell mucus secretion prevents the microor-
ganisms from sticking to the epithelial cells, thus 
preventing them from entering the human body. 
The microorganisms trapped in the mucus are me-
chanically removed by cilia movements71. It may 
happen that with the progress of the pathogenic 
process there is a transient increase in pressure 
in the sinus cavity due to accumulation of mucus. 
Then subsequently, a “negative pressure” may 
develop due to an alteration of sinus ventilation 
with a rapid absorption of oxygen by the mucosa 
cells72. Such an event worsens local congestion, 
promotes mucus retention, compromises normal 
gas exchange, reduces both oxygen and pH, pre-
vents infectious material and inflammatory debris 
from occurring, and increases the risk of a second 
bacterial infection73-76.
Discussion
Microbiotics and the Role 
of Bacterial Interference
Recent evidence supports the hypothesis that 
the microbiota of the skin and mucous mem-
branes constitutes a “superorganism”77. Mutual 
benefits for the host and microbes are numerous: 
microbes utilize a nutrient-rich environment, that 
is of the host, but in return they play a key role 
in providing a barrier against potential patho-
gens. Understanding the interactions within the 
human “superorganism” and their consequences 
for health and illness requires detailed informa-
tion on the composition of the microbiome that 
constitutes the many and distinct ecosystems of 
the human body.
The upper respiratory tract is the reservoir of 
a community of potential and pathogenic patho-
gens including Streptococcus pneumoniae (pneu-
mococcus), Haemophilus influenzae, Moraxella 
catarrhalis and Staphylococcus aureus, which 
under certain circumstances become pathogenic 
agents responsible for infectious diseases78,79. 
In order to cause respiratory diseases, the 
bacteria must first colonize the nasopharyngeal 
niche. The colonization of this niche is a complex 
dynamic process that involves the acquisition and 
elimination of species, interactions between mi-
crobes and between microbes and host, and in-
terference by environmental factors. In a state of 
equilibrium, this ecosystem, understood as part 
of the “human microbiome”, is presumed to play 
an important beneficial role for the person who 
plays the role of host80. However, imbalances in 
the respiratory microbial community can con-
tribute to the acquisition of new bacterial or viral 
pathogens, the carriage of more potent pathogenic 
bacteria, or a viral co-infection.
Subsequently, imbalances in the ecosystem 
may result in excessive growth and invasion of 
pathogenic bacteria, causing inflammatory or 
invasive diseases, particularly in children with 
immature immune systems81. Colonization of this 
niche is therefore a crucial step in the pathogen-
esis of respiratory disease82. In 1960, Hardin ar-
gued that completely competitive species cannot 
colonize the same ecological niche, indicating 
that one microorganism has the possibility of ful-
ly extinguishing another. However, the concept of 
colonization is more complex and dependent on 
several factors. For example, skin and any muco-
sal surface of the body are colonized directly after 
birth by a wide range of bacteria82. These bacteri-
al communities evolve into a complex ecosystem 
during the first years of life, varying considerably 
among individuals and over time83,84. 
Alpha-streptococci dominate the normal flora 
in the upper respiratory tract and have been the 
bacteria attracting the most attention in bacteri-
al interference. Most alpha-streptococci have the 
ability to emit bacteriocins. These are extracel-
lularly released toxins produced by the bacteria 
85 that are able to selectively kill other bacteria. 
Some bacteria release bacteriocins with a broad 
spectrum, and others release bacteriocins with a 
very narrow spectrum. Studies have shown that 
bacteriocin production is a significant ecological 
determinant in colonization. Nearly all-oral al-
pha-streptococci release inhibitory substances86, 
but bacterial interference can also occur by dif-
ferent mechanisms such as competition for sites 
at the epithelial cells, competition for specific nu-
trients, and production of substances that change 
the pH, like hydrogen peroxide7,87.
The microbiome of the upper respiratory tract 
niche seems to be influenced by the host genetic 
background, age, and environmental factors such 
as social status, antibiotic use, vaccination, sea-
sonality, cigarette smoking, social contacts, and 
number of siblings2,24. Studies88 have shown a de-
crease in normal flora after antibiotic treatment 
in URTI. 
A decreased number of alpha-streptococci, 
with interfering efficacy against beta-streptococ-
ci, have also been found on the tonsils of patients 
with recurrent streptococcal pharyngo-tonsillitis, 
compared with healthy individuals89. Grahn and 
Holm90, in a study of an outbreak of streptococcal 
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tonsillitis in an apartment house area, have shown 
that individuals with interfering alpha-strepto-
cocci on their tonsils less often acquired strepto-
coccal pharyngo-tonsillitis than patients lacking 
these bacteria. Lower numbers of alpha-strepto-
cocci have been found in otitis-prone children 
compared with non-otitis prone children33, and 
in patients with secretory otitis media compared 
with healthy children34. Tano et al31 and Brook 
and Gober11 recently found that alpha-strepto-
cocci in children with recurrent OMA and SOM 
had less inhibiting activity against pneumococci 
and H. influenzae compared with alpha-strep-
tococci isolated from healthy children. Addi-
tionally, site-specific factors and characteristics 
of the microorganism itself also play a role. By 
colonizing a niche, a microbe should be able to 
survive local clearance mechanisms (i.e., mucus, 
ciliae, etc.), attach to the epithelium, rely on lo-
cally available nutrients, and bypass surveillance 
by the host immune system82. Another essential 
condition for colonization is to outcompete in-
habitants that were already present in the upper 
respiratory tract91,92. S. pneumoniae, H. influen-
zae, M. catarrhalis are etiologic agents common-
ly recognized in URTI and the colonization by 
these species is also very common under healthy 
circumstances, with a high colonization rate es-
pecially in children2,26,93-96. However, bacterial 
commensals are thought to play an important role 
in preventing respiratory and invasive disease82. 
Sanders et al47 and later Grahn et al97 showed 
that some alpha-streptococci may have an inhib-
iting capacity on group A streptococci in vitro. 
These data support the importance of bacterial 
interference in maintaining the balance between 
resident flora and pathogenic microorganisms2. 
Since these colonizing microorganisms share the 
natural niche with other non-pathogenic microor-
ganisms, it is probable that these species interact 
with each other even in the absence of pathology. 
Microorganisms compete for nutrients and space, 
and when microorganisms overwhelm the native 
saprophytes of that niche, they can colonize; da 
Lilja et al98 documented beta-hemolytic strepto-
cocci in tonsillary epithelial cells of patients with 
acute tonsillitis symptoms, as opposed to those 
found in asymptomatic patients, where these bac-
teria did not adhere to the epithelial cells but were 
found only on the surface mucous layer.
Maintaining normal pharyngeal flora can con-
tribute to preventing or reducing recurrent in-
fections7 or preventing colonization by potential 
pathogens7,14. Bacteriotherapy, the use of harm-
less bacteria to counteract pathogenic organisms, 
is an alternative and promising way of combating 
bacterial infections12.
The Role of Bacteriotherapy 
The worldwide emergency of bacterial resis-
tance to antibiotics has led to the need for new 
methods of combating bacterial infections10,12. 
This emergency is aggravated by the long delay in 
the development of new antibacterial strategies12. 
If the design of new agents proves to be in the 
right direction,such progress would not solve all 
current resistance problems12. Penicillin-specif-
ic antibiotic therapies99 of streptococcal pharyn-
geal infections, in line with current therapeutic 
recommendations and guidelines, fails in about 
35% of treatments: alpha-streptococci bacteria 
are believed to play an important role in preven-
tion, colonization, and subsequent infection as a 
part of beta-hemolytic streptococci, and their ab-
sence in the 3 weeks following antibiotic therapy 
may favor recurrence of episodes and, therefore, 
a failure of treatment100. While targeting resistant 
bacteria, antibacterial agents also disrupt nor-
mal human flora, further reducing our defenses 
against infection12 and, more generally, negatively 
affecting normal bacterial flora101. 
The accessible surfaces of the skin, spleen cav-
ities, upper respiratory tract, gastrointestinal tract 
and vagina of healthy vertebrates are colonized by 
microbes immediately after birth102. The process is 
a dynamic, orderly succession of microbial acquisi-
tions and site-specific eliminations102. Collectively 
known as the normal microflora or indigenous mi-
crobiota, these microbes are the body’s first line of 
defense against pathogenic invasion102. 
The basis of replacement therapy is the im-
plantation and persistence within the normal mi-
croflora of relatively innocuous “effector” bacte-
ria that can competitively exclude or prevent the 
outgrowth of potentially disease-causing bacte-
ria, without significantly disturbing the balance 
of the existing microbial ecosystem102.
An early attempt to recolonize the high respira-
tory tract ecosystems was documented by Sprunt 
and Leidy103, who reported that a single inocula-
tion of intensive-care infants with alpha-strepto-
cocci isolated from normal flora, in order to avoid 
excessive growth of pathogens, helped restore the 
balance of microflora of most of the infants within 
48-72 hours; the authors concluded that this ap-
proach was safe in the neonatal population. Fur-
ther studies104-106 evaluated the use of inoculation 
of the pharyngeal niche with an alpha-streptococ-
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ci pool, in order to prevent relapsed streptococcus 
pharyngitis. Alpha-streptococci are significantly 
reduced in subjects suffering from pathologies 
in the pharyngeal district107 and, conversely, the 
presence of this bacterial family is associated with 
a significant reduction in the risk of recurrent in-
fectious diseases in the pharyngeal district108. The 
inoculation agent of alpha-streptococci was used 
in these studies because patients treated with an-
tibiotics often have pharyngeal flora that becomes 
completely deregulated with the likely deficiency 
of alpha-streptococci, which have an interfering 
activity against beta-hemolytic streptococci. 
Roos et al104 conducted a randomized, double 
blind, placebo-controlled study that enrolled 36 pa-
tients with relapsing streptococcal tonsils, who first 
underwent antibiotic therapy for 10 days; 19 patients 
were then treated with an oral spray comprising 4 
strains selected from alpha-streptococci, and 17 pa-
tients received placebo. None of the patients in the 
intervention group presented a new episode of ton-
sillitis during the 3-month follow-up period, while 
7 of 17 patients in the control group had a tonsillitis 
episode (p <0.05); after 3 months of follow-up, 1 pa-
tient in the first group vs. 11 in the control group pre-
sented an episode of tonsillitis. The authors suggest 
that recombination with alpha-streptococci offers a 
new way of lowering the rate of recurrence in strep-
tococcal pharyngeal infections. 
Roos et al105 extended their research with a ran-
domized, double-blind, placebo-controlled, multi-
center study involving 130 patients with recurrent 
episodes of streptococcal pharyngeal tonsillitis. 
Patients received antibiotics for 10 days, followed 
by 5 days of topical spray therapy with alpha-strep-
tococci in the intervention group vs. placebo in 
the other group. Clinical recurrences (bacteriolog-
ically verified) in the treatment group of patients 
were 2%, vs. 23% of patients treated with place-
bo (p<0.004). The authors conclude that the spray 
treatment with alpha-streptococci, used for at least 
5 days, significantly reduces the pharyngo-tonsilli-
tis infectious recurrence episodes.
Falck et al104 conducted a randomized, dou-
ble-blind, placebo-controlled, multicenter study 
involving 342 tonsillitis patients treated with an-
tibiotic therapy for 10 days, then segmented into 
treatment with topical alpha-streptococci (n=189) 
and placebo control (n=93). At 75-day follow-up, 
recurrence rates were treatment group 19% and 
control group 30% (p=0.037). No serious adverse 
events were reported.
Diagnosis of AOM requires adequate expe-
rience and procedure to ensure precise differen-
tial diagnosis, particularly with respect to otitis 
media with effusion. Moreover, AOM therapy is 
controversial; many guidelines suggest watchful 
waiting for mild-to-moderate episodes in children 
aged >2 years. However, in clinical practice, anti-
biotics are frequently prescribed, ignoring guide-
lines and their underlying precepts109. Prevention 
of recurrent AOM is even more debated. At pres-
ent, no evidence on proposed treatments, conven-
tional and otherwise, is definitively convincing.
A randomized, double-blind, placebo-con-
trolled clinical trial on efficacy and tolerability of 
intranasal administration of Streptococcus sali-
varius 24SMB was conducted in the treatment 
of acute otitis in children with a history of acute 
recurrent otitis media 110. The study recruited 100 
patients aged between 1 and 5 years with a history 
of acute recurrent otitis media (3 episodes in the 
previous 6 months or 4 episodes in the previous 12 
months with the last episode in the previous 2-8 
weeks) and intranasally administered S. salivarius 
24SMB (n=50) or placebo (n=47) twice daily for 5 
days per month for 3 consecutive months. Partici-
pants were followed for 6 months (3 months each 
treatment and follow up). Treated children were 
twice as likely not to manifest acute otitis media 
at follow up compared to children in the placebo 
group (30.0% vs. 14.9%; p=0.076). In addition, the 
number of children who received antibiotics during 
the study period was lower in children treated with 
S. salivarius 24SMB compared to those who re-
ceived placebo. Compared with children who were 
not colonized by S. salivarius 24SMB after treat-
ment, the number of colonized children who ex-
perienced any acute otitis was significantly lower. 
Similar results were observed considering antibi-
otic treatment; the number of colonized children 
using antibiotics was significantly lower compared 
with non-colonized children. This study, designed 
in part to evaluate a nasal delivery device, revealed 
the ability of S. salivarius 24SMB nasal spray to 
reduce the risk of AOM in children110,111.
Recently, a retrospective and observational 
study demonstrated that S. salivarius 24SMB and 
S. oralis 89a nasal spray could be effective in the 
prevention of recurrent AOM in a real-life setting. 
S. salivarius 24SMB and Streptococcus oralis 89a 
nasal spray was administered to 159 children af-
ter the first AOM episode; 108 children received 
no bacteriotherapy and served as control. Active 
treatment consisted of 3 monthly courses: 2 puffs 
per nostril twice/day for a week. The intervention 
group showed a significant reduction of AOM epi-
sodes in comparison with controls (p<0.0001). No-
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tably, all actively treated children with the highest 
AOM recurrence had a reduction of recurrence, 
whereas only 50% of the control group children 
had reduced recurrent AOM (p<0.0001)112.
Interference between normal flora and patho-
gens is not limited to acute streptococcal pharyn-
gotonsillitis and acute otitis media. Brook and 
Gober113 have shown that the nasopharyngeal flo-
ra and nasal flora of non-sinusitis-prone children 
contain more aerobic and anaerobic organisms 
with interfering capacity compared with the flora 
of sinusitis-prone children.
The results of these studies suggest that the use 
of bacterial interference phenomena through bacte-
riotherapy is a feasible, safe approach and deserves 
proper consideration as a therapeutic strategy. A 
basic concept for bacteriotherapy is the persistence 
in normal microflora of relatively harmless “effica-
cious” bacteria, which can competitively exclude 
or inhibit the growth of potentially pathogenic bac-
teria without significantly disturbing the balance 
of the existing microbial ecosystem114. Large-spec-
trum antibiotics administered parenterally indis-
criminately kill a wide variety of bacterial spe-
cies associated with the host microflora, causing 
the formation of an “ecological vacuum” and en-
couraging the development of superinfections and 
bacterial resistance to antibiotics102. Replacement 
therapy, i.e. the direct implantation of relatively 
harmless bacteria known as being highly competi-
tive against potential pathogens, provides favorably 
cost-effective and long-term protection tailored to 
the host against specific bacterial infections102. In 
the literature bacteriotherapy has been trialed in 
dental caries, using S. mutans JH 1000115; L. rham-
nosus GG116; S. equi117; S. salivarius118; S. faeca-
lis119; in otitis media using Streptococcus salivarius 
24SMB, S. sanguinis, S. mitis and S. oralis15,110,120; 
in streptococcal pharyngitis using S. salivarius 
K12104 or S. sanguinis and S. mitis together104,105; in 
pseudomembranous colitis after antibiotic therapy 
to counteract Clostridium difficile infection121; and 
in ulcerative colitis by replanting the bacterial flora 
of the stools of the same patient122.
Conclusions
The results of previous studies on the role 
of bacteriotherapy in paediatric URTI suggest 
that the use of bacterial interference phenomena 
through bacteriotherapy is a feasible, safe ap-
proach and deserves proper consideration as a 
promising therapeutic strategy in URTI.
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